text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 117570-53-3 | Product Number: D5235

Vadimezan


Purity: >98.0%(HPLC)
Synonyms:
  • DMXAA
  • 2-(5,6-Dimethyl-9-oxoxanthen-4-yl)acetic Acid
  • ASA-404
Product Documents:
50MG
¥14,100
10   It can be shipped from Saitama warehouse on the same day* Contact Us
250MG
¥45,400
4   17   Contact Us
* Available Stock: Prompt shipment (for products) in Saitama/Hyogo warehouse. Stock In Other WH: Shipment in about 2-3 Business Days from Saitama warehouse. Please contact us if you need further information.
* The displayed price is the unit price and does not include consumption tax. The unit prices displayed are the latest and are subject to change without notice.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Product Number D5235
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__1__7H__1__4O__4 = 282.30 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Condition to Avoid Heat Sensitive
Packaging and Container 250MG-Glass Bottle with Plastic Insert (View image),  50MG-Glass Bottle with Plastic Insert (View image)
CAS RN 117570-53-3
Reaxys Registry Number 4262852
PubChem Substance ID 468591309
MDL Number

MFCD00870555

Specifications
Appearance White to Light yellow powder to crystal
Purity(HPLC) min. 98.0 area%
Properties (reference)
Melting Point 264 °C
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H302 : Harmful if swallowed.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P270 : Do not eat, drink or smoke when using this product.
P264 : Wash skin thoroughly after handling.
P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.
Related Laws:
RTECS# ZD5536200
Transport Information:
Application
DMXAA: A Compound Used as a Tumor Vascular Disputing Agent and an Immune Adjuvant

DMXAA (other names: vadimezan, ASA404) is a tumor vascular disputing agent (VDA) that can cause a specific and irreversible destruction of established tumor vessels. Reportedly, DMXAA induces apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core. DMXAA showed anti-tumor effects against solid tumors in mouse models but subsequently failed in human clinical trials in 2010.
DMXAA is also a potent type-I interferon (IFN) inducer, and can be used as an adjuvant that targets a specific innate immune signaling pathway. (The product is for research purpose only.)

References


Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.